Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CLDN18.2 expression
i
Other names:
CLDN18, Claudin-18, Surfactant, Pulmonary Associated Protein J, Surfactant Associated 5, SFTA5, SFTPJ
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
51208
Related biomarkers:
Expression
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
CLDN18.2 expression
Endometrial Cancer
CLDN18.2 expression
Endometrial Cancer
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
Clin Cancer Res - 1 week (New D)
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
Clin Cancer Res - 1wk
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
Clin Cancer Res - 1 week
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
Clin Cancer Res - 1 week - (New D)
CLDN18.2 expression
Ovarian Cancer
CLDN18.2 expression
Ovarian Cancer
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
Clin Cancer Res - 1 week (New D)
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
Clin Cancer Res - 1wk
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
Clin Cancer Res - 1 week
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
Clin Cancer Res - 1 week - (New D)
CLDN18.2 expression
Lung Adenocarcinoma
CLDN18.2 expression
Lung Adenocarcinoma
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks (New D)
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2wk
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2 weeks - (New D)
CLDN18.2 expression
Colon Cancer
CLDN18.2 expression
Colon Cancer
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks (New D)
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2wk
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2 weeks - (New D)
CLDN18.2 expression
Hepatocellular Cancer
CLDN18.2 expression
Hepatocellular Cancer
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks (New D)
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2wk
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2 weeks - (New D)
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks (New D)
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2wk
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2 weeks - (New D)
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks (New D)
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2wk
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2 weeks - (New D)
CLDN18.2 expression
Esophageal Adenocarcinoma
CLDN18.2 expression
Esophageal Adenocarcinoma
IMAB362
Sensitive: C2 – Inclusion Criteria
IMAB362
Sensitive
:
C2
IMAB362
Sensitive: C2 – Inclusion Criteria
IMAB362
Sensitive
:
C2
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
IMAB362
Sensitive: C2 – Inclusion Criteria
IMAB362
Sensitive
:
C2
IMAB362
Sensitive: C2 – Inclusion Criteria
IMAB362
Sensitive
:
C2
CLDN18.2 expression
Gastric Adenocarcinoma
CLDN18.2 expression
Gastric Adenocarcinoma
IMAB362
Sensitive: C2 – Inclusion Criteria
IMAB362
Sensitive
:
C2
IMAB362
Sensitive: C2 – Inclusion Criteria
IMAB362
Sensitive
:
C2
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
Q-1802
Sensitive: C3 – Early Trials
Q-1802
Sensitive
:
C3
Q-1802
Sensitive: C3 – Early Trials
Q-1802
Sensitive
:
C3
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
CLDN18.2 expression
Solid Tumor
CLDN18.2 expression
Solid Tumor
TJ-CD4B
Sensitive: D – Preclinical
TJ-CD4B
Sensitive
:
D
TJ-CD4B
Sensitive: D – Preclinical
TJ-CD4B
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login